Skip to main content

Deal Structure Trade Space

Most BD conversations anchor on licensing because that’s the default. But the same asset could be 20–60% more valuable under a different structure — or significantly less. Below are four representative assets run through all five deal structures, ranked by total value to the licensor.

Computed by optimizeDealStructure() (backtest-validated engine). Upfront, milestone allocation, and royalty structures vary by deal type per the DEAL_TYPE_CAPTURE and PHASE_ALLOCATION tables. All figures in $M unless noted otherwise.

Interactive

Run Your Own Asset

Configure an asset profile below and the engine will rank all five deal structures in real time.

Asset Profile

Peak Sales Estimates ($M)

Buyer (optional)

If the buyer is in our counterparty database, we'll show their historical deal premium.

Reference Scenarios

Four representative assets pre-computed for comparison.

Phase 2 oncology mAb

NSCLC, $2B peak, small-biotech licensor

TA: oncologyPhase: phase2Modality: mabPeak: $2000M
Recommendation (strong)

Your asset would be worth 422% more as a Acquisition (M&A) ($652M) than as Licensing ($125M). Based on phase2 oncology benchmarks and your licensor profile, this structure better matches the asset's stage and the typical buyer behavior in this space.

Recommended

Acquisition

#1

Cash now for full ownership. Highest upfront ratio.

Upfront$652M
Total deal$652M
vs current+4%

Top-ranked: Acquisition (M&A) delivers $652M total deal value with $652M upfront (100% upfront ratio). Best fit for the licensor's risk and cash preferences.

Co-development

#2

Shared R&D cost, shared upside. Lower upfront, higher retained NPV.

Upfront$70M
Total deal$316M
vs current+2%

Co-development: $316M total (22% upfront) — 153% better than your selection.

Collaboration

#3

Research funding + joint milestones. Early-stage partnership.

Upfront$36M
Total deal$182M
vs current+0%

Research Collaboration: $182M total (20% upfront) — 46% better than your selection.

Licensing

#4

Upfront + milestones + royalties. Standard bio-pharma template.

Upfront$67M
Total deal$125M
vs current+0%

Licensing: $125M total — comparable to your selection (within 20%).

Option

#5

Small option fee now + larger exercise fee after data. Probability-weighted.

Upfront$11M
Total deal$140M
vs current+0%

Option / License: $140M total — comparable to your selection (within 20%).

Phase 3 rare disease gene therapy

DMD, $500M peak, orphan designation

TA: rareDiseasePhase: phase3Modality: geneTherapyPeak: $500M
Recommendation (strong)

Your asset would be worth 254% more as a Acquisition (M&A) ($980M) than as Licensing ($277M). Based on phase3 rareDisease benchmarks and your licensor profile, this structure better matches the asset's stage and the typical buyer behavior in this space.

Recommended

Acquisition

#1

Cash now for full ownership. Highest upfront ratio.

Upfront$980M
Total deal$980M
vs current+3%

Top-ranked: Acquisition (M&A) delivers $980M total deal value with $980M upfront (100% upfront ratio). Best fit for the licensor's risk and cash preferences.

Co-development

#2

Shared R&D cost, shared upside. Lower upfront, higher retained NPV.

Upfront$101M
Total deal$387M
vs current+0%

Co-development: $387M total (26% upfront) — 40% better than your selection.

Licensing

#3

Upfront + milestones + royalties. Standard bio-pharma template.

Upfront$131M
Total deal$277M
vs current+0%

Licensing: $277M total — comparable to your selection (within 20%).

Collaboration

#4

Research funding + joint milestones. Early-stage partnership.

Upfront$73M
Total deal$318M
vs current+0%

Research Collaboration: $318M total — comparable to your selection (within 20%).

Option

#5

Small option fee now + larger exercise fee after data. Probability-weighted.

Upfront$19M
Total deal$188M
vs current-0%

Option / License: $188M total — 32% lower than your selection.

Phase 2 immunology bispecific

Atopic dermatitis, $1.5B peak, mid-biotech licensor

TA: immunologyPhase: phase2Modality: bispecificPeak: $1500M
Recommendation (strong)

Your asset would be worth 283% more as a Acquisition (M&A) ($414M) than as Licensing ($108M). Based on phase2 immunology benchmarks and your licensor profile, this structure better matches the asset's stage and the typical buyer behavior in this space.

Recommended

Acquisition

#1

Cash now for full ownership. Highest upfront ratio.

Upfront$414M
Total deal$414M
vs current+3%

Top-ranked: Acquisition (M&A) delivers $414M total deal value with $414M upfront (100% upfront ratio). Best fit for the licensor's risk and cash preferences.

Co-development

#2

Shared R&D cost, shared upside. Lower upfront, higher retained NPV.

Upfront$50M
Total deal$228M
vs current+1%

Co-development: $228M total (22% upfront) — 111% better than your selection.

Collaboration

#3

Research funding + joint milestones. Early-stage partnership.

Upfront$26M
Total deal$133M
vs current+0%

Research Collaboration: $133M total (20% upfront) — 23% better than your selection.

Licensing

#4

Upfront + milestones + royalties. Standard bio-pharma template.

Upfront$60M
Total deal$108M
vs current+0%

Licensing: $108M total — comparable to your selection (within 20%).

Option

#5

Small option fee now + larger exercise fee after data. Probability-weighted.

Upfront$10M
Total deal$125M
vs current+0%

Option / License: $125M total — comparable to your selection (within 20%).

Phase 1 platform RNAi

Cardiovascular, $400M peak, early-stage option play

TA: cardiovascularPhase: phase1Modality: rnaiPeak: $400M
Recommended

Co-development

#1

Shared R&D cost, shared upside. Lower upfront, higher retained NPV.

Upfront$16M
Total deal$159M
vs current+0%

Top-ranked: Co-development delivers $159M total deal value with $16M upfront (10% upfront ratio). Best fit for the licensor's risk and cash preferences.

Option

#2

Small option fee now + larger exercise fee after data. Probability-weighted.

Upfront$7M
Total deal$109M
vs current+0%

Option / License: $109M total — comparable to your selection (within 20%).

Collaboration

#3

Research funding + joint milestones. Early-stage partnership.

Upfront$5M
Total deal$71M
vs current+0%

Research Collaboration: $71M total — comparable to your selection (within 20%).

Licensing

#4

Upfront + milestones + royalties. Standard bio-pharma template.

Upfront$-81M
Total deal$-81M
vs current+0%

Licensing: $-81M total — comparable to your selection (within 20%).

Acquisition

#5

Cash now for full ownership. Highest upfront ratio.

Upfront$-424M
Total deal$-168M
vs current+0%

Acquisition (M&A): $-168M total — comparable to your selection (within 20%).

How we compute this

For each asset, the engine runs calculateRNPV() five times — one per deal type. Peak sales, PoS, discount rate, and cash flow timing are constant across runs; only deal-type-specific upfront / milestone / royalty structure varies. The resulting implied deal values are the headline numbers shown in each card.

Rankings apply a licensor preference profile: clinical-stage biotechs with short cash runway weight cash-now higher, large pharma weights retained upside higher. The profile shifts ties but doesn’t override a meaningfully better headline value.

We surface a recommendation only when the top alternative beats the user’s current structure by ≥20%. Below that threshold, the signal is too weak to override the strategic context (tax, IP, control, relationship dynamics) that drive the choice in practice. This tool informs the conversation; it doesn’t replace it.

Stay Informed

Weekly Deal Intelligence Digest

Get benchmark updates, deal structure shifts, and market intelligence delivered to your inbox.

No spam. Unsubscribe anytime.

Deal Structure Trade Space | Solidus | Ambrosia Ventures